The relationship between opioid and sugar intake: Review of evidence and clinical applications
Keywords:opioid, sugar, weight gain, diabetes, analgesia
AbstractOpioid dependence poses significant public health risks arising from associated morbidity and mortality caused by accidents, infectious diseases, and social ramifications of crime and unemployment, among other complications. Opioid use, acute and chronic, is also associated with weight gain, glycemic dysregulation, and dental pathology. The literature supporting the connection between opiate use and development of preference for sweet tastes is reviewed, and further association with dental pathology, weight gain, and loss of glycemic control are considered. Additionally, the impact of sweet tastes on the endogenous opioid system, as pertaining to analgesia, is also discussed. The authors discuss the clinical implications in relation to the aforementioned conditions while treating the opiate-dependent patient.
Borg L, Kravets I, Kreek MJ: The pharmacology of long-acting as contrasted with short-acting opioids. In Ries RK, Fiellin DA, Miller SC, et al. (eds.): Principles of Addiction Medicine. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2009: 117-131.
Kolarzyk E, Chrostek MJ, Pach D, et al.: Assessment of daily nutrition ratios of opiate-dependent persons before and after 4 years of methadone maintenance treatment. Przegl Lek. 2005; 62(6): 368-372.
Zador D, Lyons Wall PM, Webster I: High sugar intake in a group of women on methadone maintenance in South Western Sydney, Australia. Addiction. 1996; 91(7): 1053-1061.
Nolan LJ, Scagnelli LM: Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Subst Use Misuse. 2007; 42: 1555-1566.
Morabia A, Fabre J, Chee E, et al.: Diet and opiate addiction: A quantitative assessment of the diet of non-institutionalized opiate addicts. Br J Addict. 1989; 84: 173-180.
Bogucka-Bonikowska A, Baran-Furga H, Chmielewska K, et al.: Taste function in methadone-maintained opioid-dependent men. Drug Alcohol Depend. 2002; 68: 113-117.
Dum J, Gramsch CH, Herz A: Activation of hypothalamic Bendorphin pools by reward induced by highly palatable food. Pharmacol Biochem Behav. 1983; 18: 443-447.
Bodnar RJ, Glass MJ, Ragnauth A, et al.: General, mu and kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions. Brain Res. 1995; 700: 205-212.
Koch JE, Glass MJ, Cooper ML, et al.: Alterations in deprivation, glucoprivic and sucrose intake following general, mu and kappa opioid antagonists in the hypothalamic paraventricular nucleus of rats. Neuroscience. 1995; 66(4): 951-957.
Kelley AE, Bless EP, Swanson CJ: Investigation into the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. J Pharmacol Exp Ther. 1996; 278(3): 1499-1507.
Echo JA, Lamonte N, Ackerman TF, et al.: Alterations in food intake elicited by GABA and opioid agonists and antagonists administered into the entral tegmental area region of rats. Physiol Behav. 2002; 76: 107-116.
Zhang M, Kelley AE: Intake of saccharin, salt, and ethanol solutions is increased by infusion of a mu opioid agonist into the nucleus accumbens. Psychopharmacology. 2002; 159: 415-423.
Colantuoni C, Schwenker J, McCarthy J, et al.: Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain. Neuroreport. 2001; 12: 3549-3552.
Spangler R, Wittkowski KM, Goddard NL, et al.: Opiate-like effects of sugar on gene expression in reward areas of the rat brain. Mol Brain Res. 2004; 124: 134-142.
Avena NM, Rada P, Hoebel BG: Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake. Neurosci Behav Rev. 2008; 32: 20-39.
Yeomans MR, Wright P, Macleod HA, et al.: Effects of nalmefene on feeding in humans. Psychopharmacology. 1990; 100: 426-432.
Gosnell BA, Krahn DD: The effects of continuous naltrexone infusions on diet preferences are modulated by adaptation to the diets. Physiol Behav. 1992; 51(2): 239-244.
Drewnowski A, Krahn D, Demitrack MA, et al.: Naloxone, an opiate blocker, reduces consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr. 1995; 61: 1206-1212.
Yeomans MR, Gray RW: Opioid peptides and the control of human ingestive behavior. Neurosci Behav Rev. 2002; 26: 713-728.
Sahr AE, Sindelar DK, Alexander-Chacko JT, et al.: Activation of mesolimbic dopamine neurons during novel and daily limited access to palatable food is blocked by the opioid antagonist LY255582. Am J Physiol Regul Integr Comp Physiol. 2008; 295: R463-R471.
Gaiardi M, Gubellini C, Bartoletti M: Taste conditioning effects of buprenorphine in morphine-naïve and morphine-experienced rats. Pharmacol Res. 1998; 37(4): 303-307.
Comer SD, Evans SM, Pudiak CM, et al.: Effects of buprenorphine on candy and sweetened fluid self-administration by rhesus monkeys. Psychopharmacology. 2002; 164: 200-206.
Mello NK, Lukas SE, Kamien JB, et al.: The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 1992; 260: 1185-1193.
Hood S, Sorge RE, Stewart J: Chronic buprenorphine reduces the response to sucrose-associated cues in nonfood-deprived rats. Pharmacol Biochem Behav. 2007; 86: 566-575.
Sapira JD: The narcotic addict as a medical patient. Am J Med. 1968; 45: 555-588.
Lieblich I, Yirmiya R, Liebeskind JC: Intake of and preference for sweet solutions are attenuated in morphine-withdrawn rats. Behav Neurosci. 1991; 105(6): 965-970.
Rajs J, Petersson A, Thiblin I, et al.: Nutritional status of deceased illicit drug addicts in Stockholn, Sweden—A longitudinal medicolegal study. J Forensic Sci. 2004; 49(2): 1-10.
Mohs, ME, Watson RR, Leonard-Green T: Nutritional effects of marijuana, heroin, cocaine, and nicotine. J Am Diet Assoc. 1990; 90: 1261-1267.
Levine AS, Atkinson RL: Opioids in the regulation of food intake and energy expenditure. Fed Proc. 1987; 46(1): 159-161.
Atkinson RL: Opioid regulation of food intake and body weight in humans. Fed Proc. 1987; 46(1): 178-182.
Yuan CS, Wang CZ, Attele A, et al.: Methylnaltrexone reduced body weight gain in ob/ob mice. J Opioid Manage. 2009; 5(4): 213-218.
David CA, Levitan RD, Reid C, et al.: Dopamine for ‘wanting’ and opioids for ‘liking’: A comparison of obese adults with and without binge eating. Obesity. 2009; 17(6): 1220-1225.
Shalev U, Yap J, Shaham Y: Leptin attenuates acute food deprivation-induced relapse to heroin seeking. J Neurosci. 2001; 21(4): RC129.
Trinko R, Sears RM, Guarnieri DJ, et al.: Neural mechanisms underlying obesity and drug addiction. Physiol Behav. 2007; 91: 499-505.
Belknap JK, Crabbe JC, Young ER: Voluntary consumption of ethanol in 15 inbred mouse strains. Psychopharmacology. 1993; 112: 503-510.
Acosta MC, Manubay J, Levin FR: Pediatric obesity: Parallels with addiction and treatment recommendations. Harv Rev Psychiatry. 2008; 16(2): 80-96.
Reed JL, Ghodse AH: Oral glucose tolerance and hormonal response in heroin-dependent males. Br Med J. 1973; 2: 582-585.
Willenbring ML, Morely JE, Krahn DD, et al.: Psychoneuroendocrine effects of methadone maintenance. Psychoneuroendocrinology. 1989; 14(5): 371-379.
Ceriello A, Giugliano D, Passariello N, et al.: Impaired glucose metabolism in heroin and methadone users. Horm Metab Res. 1987; 19(9): 430-433.
Sullivan SN, Lee MG, Bloom SR, et al.: Reduction by morphine of human postprandial insulin release is secondary to inhibition of gastrointestinal motility. Diabetes. 1986; 35(3): 324-328.
Mehendale SR, Yuan CS: Opioid-induced gastrointestinal dysfunction. Dig Dis. 2006; 24: 105-112.
Sadava D, Alonso D, Hong H, et al.: Effects of methadone addiction on glucose metabolism in rats. Gen Pharmacol. 1997; 28(1): 27-29.
Giugliano D: Morphine, opioid peptides, and pancreatic islet function. Diabetes Care. 1984; 7(1): 92-98.
Bullingham RES, McQuay HJ, Dwyer D, et al.: Sublingual buprenorphine used postoperatively: Clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol. 1981; 12: 117-122.
Fareed A, Casarela J, Amar R, et al.: Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. J Psychiatr Pract. 2009; 15: 227-234.
Tiras S, Haas V, Chevret L, et al.: Nonketotic hyperglycemic coma in toddlers after unintentional methadone ingestion. Ann Emerg Med. 2006; 48(4): 448-451.
Blass EM, Fitzgerald E, Kehoe P: Interactions between sucrose, pain, and isolation distress. Pharmacol Biochem Behav. 1987; 26: 483-489.
Mitchell A, Waltman PA: Oral sucrose and pain relief for preterm infants. Pain Manag Nurs. 2003; 4(2): 62-69.
Ramenghi LA, Wood CM, Griffith GC, et al.: Reduction of pain response in premature infants using intraoral sucrose. Arch Dis Child. 1996; 74: F126-F128.
Ramenghi LA, Griffith GC, Wood LA, et al.: Effects of non-sucrose sweet tasting solution on neonatal heel prick responses. Arch Dis Child. 1996; 74(2): F129-F131.
Ramenghi LA, Evans DJ, Levene ME: Sucrose analgesia: Absorptive mechanism or taste perception? Arch Dis Child Fetal Neonatal Ed. 1999; 80: 146-147.
Barr RG, Pantel MS, Young SN, et al.: The response of crying newborns to sucrose: Is it a “sweetness” effect? Physiol Behav. 1999; 66(3): 409-417.
Blass EM, Ciaramitaro V: Oral determinants of state, affect, and action in newborn humans. Monogr Soc Res Child Dev. 1994; 59: 1-96.
Taddio A, Shah V, Shah P, et al.: B-Endorphin concentration after administration of sucrose in preterm infants. Arch Pediatr Adolesc Med. 2003; 157: 1071-1074.
Miller A, Barr RG, Young SN: The cold pressor test in children: Methodological aspects and the analgesic effect of intraoral sucrose. Pain. 1994; 56: 175-183.
Mercer ME, Holder MD: Antinociceptive effects of palatable sweet ingesta on human responsivity to pressure pain. Physiol Behav. 1997; 61(2): 311-318.
Anseloni VCZ, Weng HR, Terayama R, et al.: Age-dependency of analgesia elicited by intraoral sucrose in acute and persistent pain models. Pain. 2002; 97(1-2): 93-103.
Lewkowski MD, Barr RG, Sherrard A, et al.: Effects of chewing gum on responses to routine painful procedures in children. Physiol Behav. 2003; 79(2): 257-265.
Lewkowski MD, Young SN, Ghosh S, et al.: Effects of opioid blockade on the modulation of pain and mood by sweet taste and blood pressure in young adults. Pain. 2008; 135: 75-81.
Fontella FU, Nunes ML, Crema LM, et al.: Taste modulation of nociception differently affects chronically stressed rats. Physiol Behav. 2004; 80: 557-561.
Kanarek RB, Homoleski B: Modulation of morphine-induced antinociception by palatable solutions in male and female rats. Pharmacol Biochem Behav. 2000; 66(3): 653-659.
Klein SP, Green KF: Tolerance to morphine analgesia from brief exposure to a palatable solution. Brain Res Bull. 1988; 21: 963-965.
Reece AS: Dentition of addiction in Queensland: Poor dental status and major contributing drugs. Aust Dent J. 2007; 52(2): 144-149.
Titsas A, Ferguson MM: Impact of opioid use on dentistry. Aust Dent J. 2002; 47(2): 94-98.
Reece AS: An intriguing association between dental and mental pathology in addicted and control subjects: A cross-sectional survey. Br Dent J. 2008; 205(E22): 1-8.
Nathwani NS, Gallagher JE: Methadone: Dental risks and preventive action. Dent Update. 2008; 35(8): 542-544, 547-548.
Federman AD, Arnsten JH: Primary care affiliations of adults in a methadone program with onsite care. J Addict Dis. 2007; 26(1): 27-34.
Spiegel TA, Stunkard AJ, Shrager EE, et al.: Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiol Behav. 1987; 40(2): 135-141.
Atkinson RL, Berle LK, Drake CR, et al.: Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther. 1985; 38(4): 419-422.
Maggio CA, Presta E, Bracco EF, et al.: Naltrexone and human eating behavior: A dose-ranging inpatient trial in moderately obese men. Brain Res Bull. 1985; 14(6): 657-661.
Mitchell JE, Morley JE, Levine AS, et al.: High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry. 1987; 221(1): 35-42.
Malcolm R, O’Neil PM, Sexauer JD, et al.: A controlled trial of naltrexone in obese humans. Int J Obes. 1985; 9(5): 347-353.
Pfohl DN, Allen JI, Atkinson RL, et al.: Naltrexone hydrochloride (Trexan): A review of serum transaminase elevations at high dosage. NIDA Res Monogr. 1986; 67: 66-72.
Orexigen Press Release: Contrave® obesity research phase 3 program meets co-primary and key secondary endpoints; Exceeds FDA efficacy benchmark for obesity treatments, San Diego. Available at www.Orexigen.com. Accessed July 20, 2009.
Greenway FL, Whitehouse MJ, Guttadauria M, et al.: Rational design of a combination medication for the treatment of obesity. Obesity. 2009; 17(1): 30-39.
Greenway FL, Dunayevich E, Tollefson G, et al.: Comparison of combined buproprion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009; 94(12): 4898-4906.
Recant L, Voyles NR, Luciano M, et al.: Naltrexone reduces weight gain, alters “beta-endorphin”, and reduces insulin output from pancreatic islets of genetically obese mice. Peptides. 1908; 1(4): 309-313.
De Marinis L, Mancini A, Valle D, et al.: Influence of chronic naltrexone treatment on growth hormone and insulin secretion in obese subjects. Int J Obes Relat Metab Disord. 1997; 21(11): 1076-1081.
Dey PK, Feldberg W: Hyperglycemia produced by drugs with analgesic properties introduced into cerebral ventricles of cats. Br J Pharmacol. 1975; 54: 163-170.
How to Cite
Copyright 2005-2023, Weston Medical Publishing, LLC
All Rights Reserved